Reporter brief
An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines
What happened
Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- This is a protocol description without reported outcomes; it does not demonstrate that the intervention had any effect on inflammatory cytokines
- Open-label design with no control group means any observed changes cannot be distinguished from placebo or natural variation
- A 7-day duration is too short to establish whether any acute changes persist or translate to meaningful health benefits
Study design and sample
Other; Human.
Adults aged 45 to 79 residing in the United States
- Design
- Other
- Sample
- —
- Journal
- Qualia Life Sciences
- Published
- May 1, 2025
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not reported. Journal is published by Qualia Life Sciences, the apparent manufacturer of the intervention product. · Not disclosed. The journal and study appear to be sponsored or conducted by the company manufacturing the intervention.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.